Compare SPB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPB | URGN |
|---|---|---|
| Founded | 1906 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1994 | 2016 |
| Metric | SPB | URGN |
|---|---|---|
| Price | $90.69 | $48.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $82.40 | $29.29 |
| AVG Volume (30 Days) | 342.0K | ★ 871.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $3,802,100,000.00 | $1,128,000.00 |
| Revenue This Year | $2.03 | $129.09 |
| Revenue Next Year | $1.85 | $70.96 |
| P/E Ratio | $87.54 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $49.99 | $15.86 |
| 52 Week High | $99.06 | $49.67 |
| Indicator | SPB | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 67.47 |
| Support Level | $79.63 | $18.23 |
| Resistance Level | $90.60 | N/A |
| Average True Range (ATR) | 3.06 | 2.45 |
| MACD | -0.22 | 0.45 |
| Stochastic Oscillator | 33.47 | 86.68 |
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.